Transcriptomics

Dataset Information

0

Characterizing the Chemoresistant Ovarian Cancer Population using the Heterogeneous PDX


ABSTRACT: The patient-derived xenograft (PDX) model retains the heterogeneity of patient tumors, allowing a means to not only examine efficacy of a therapy across a population, but also study crucial aspects of cancer biology in response to treatment. Herein we describe the development and characterization of an ovarian-PDX model in order to study the development of chemoresistance. We demonstrate that PDX tumors are not simply composed of tumor-initiating cells, but recapitulate the original tumor’s heterogeneity, oncogene expression profiles, and clinical response to chemotherapy. Combined carboplatin/paclitaxel treatment of PDX tumors enriches the cancer stem cell populations, but persistent tumors are not entirely composed of these populations. RNA-Seq analysis of treated PDX tumors compared to untreated tumors demonstrates a consistently contrasting genetic profile after therapy, suggesting similar, but few, pathways are mediating chemoresistance. The pathways most significantly altered included Protein Kinase A signaling, GNRH signaling, and sphingosine-1-phosphate signaling. Pathways and genes identified by this methodology represent novel approaches to targeting the chemoresistant population in ovarian cancer

ORGANISM(S): Homo sapiens

PROVIDER: GSE58586 | GEO | 2015/06/17

SECONDARY ACCESSION(S): PRJNA252939

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2015-06-17 | E-GEOD-58586 | biostudies-arrayexpress
2022-08-11 | PXD034246 | Pride
2021-12-05 | ST002010 | MetabolomicsWorkbench
2024-10-02 | GSE247982 | GEO
2016-05-28 | E-GEOD-81971 | biostudies-arrayexpress
2011-07-23 | E-GEOD-28739 | biostudies-arrayexpress
2024-05-17 | GSE264252 | GEO
2020-02-25 | E-MTAB-8787 | biostudies-arrayexpress
2016-05-28 | GSE81971 | GEO
| 2220019 | ecrin-mdr-crc